ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1868

Neutrophil Extracellular Trap Formation in Patients with Vasculitis

Despina Michailidou1, Runa Kuley1, Tomas Mustelin2, David Cuthbertson3, Peter Grayson4, Nader Khalidi5, CURRY LEE MD KOENING6, Carol Langford7, Carol McAlear8, Larry Moreland9, Christian Pagnoux10, Philip Seo11, Ulrich Specks12, Antoine Sreih8, Kenneth Warrington13, Paul Monach14, Peter Merkel15 and Christian Lood2, 1Division of Rheumatology, University of Washington, Seattle, WA, 2University of Washington, Seattle, WA, 3Health Informatics Institute, University of South Florida, South Florida, FL, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 5McMaster University, Hamilton, ON, Canada, 6LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, 7Cleveland Clinic, Moreland Hills, OH, 8Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 9Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 10Mount Sinai Hospital, Toronto, ON, Canada, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, Rochester, MN, 13Mayo Clinic, Rochester, Minnesota, 14Brigham and Women's Hospital, Boston, MA, 15University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2021

Keywords: ANCA associated vasculitis, Anti-histone antibodies, large vessel vasculitis, neutrophils

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Neutrophil extracellular trap (NET) formation, the extrusion of chromatin and granular components from activated neutrophils, is essential in host defense. However, NET formation has also been linked to inflammation and autoimmunity, including in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), a disease of small blood vessels. Neutrophil infiltration is seen in aortic specimens of patients with Takayasu’s arteritis (TAK) and affected arteries of giant cell arteritis (GCA), two types of large-vessel vasculitis (LVV). Whether NET formation and autoimmunity against NET antigens such as extracellular histones, a common NET-related autoantigen in other autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis, occurs in LVV is not known. The purpose of this study was to compare levels of NET formation and anti-histone antibodies across different types of vasculitis.

Methods: Plasma levels of NETs (neutrophil elastase (NE)-DNA complexes) and anti-histone antibodies were analyzed in healthy controls (n=30), and patients with AAV (granulomatosis with polyangiitis (GPA, n=196), microscopic polyangiitis (MPA, n=74)), TAK (n=66), and GCA (n=82), at times of remission or flare. Disease activity was assessed using physician global assessments (PGA).

Results: Compared to healthy controls (HC) NE-DNA complexes were significantly elevated in all patients with vasculitis, both at flare and remission, except at remission for patients with MPA (Figure 1A). In patients with TAK, but none of the other conditions, elevated levels of NE-DNA complexes were seen at time of flare as compared to remission (p< 0.05), with NE-DNA levels correlating with PGA (r=0.28, p< 0.05). Levels of NETs did not correlate with C-reactive protein, a marker of general inflammation. Only patients with TAK had significantly higher levels of anti-histone antibodies in their circulation regardless of disease activity (p< 0.01) (Figure 1B). In patients with TAK, levels of anti-histone antibodies correlated with presence of NETs (r=0.35, p< 0.01).

Conclusion: NET formation, as assessed by NE-DNA complexes, is elevated in both small- and large-vessel vasculitis, suggesting a potential common disease link across vasculitides. The association of anti-histone antibodies with NETs in TAK suggests NETs may be a source of autoantigens in this disease. Further studies are needed to explore the role of NETs and anti-histone antibodies in the pathogenesis of vasculitis.

Figure 1. Levels of NE-DNA complexes and anti-histone antibodies in patients with vasculitis. Levels of A) NE-DNA complexes and B) anti-histone antibodies were analyzed in healthy controls (HC), and patients with vasculitis at times of remission (rem) and active disease. Statistical analyses were done by Mann-Whitney U test with *p < 0.05, **p < 0.01 and ***p < 0.001. Unless otherwise indicated, all analyses are compared to healthy controls. Each circle represents an individual sample, with the bar representing the median of the group. GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; TAK: Takayasu’s arteritis; GCA: giant cell arteritis.


Disclosures: D. Michailidou, None; R. Kuley, None; T. Mustelin, None; D. Cuthbertson, None; P. Grayson, None; N. Khalidi, Roche, 12, Advisory Board for GCA CME November 2020, BMS, 12, Clinical Trial (Investigator Initiated- BMS supplied drug only, no fees received from BMS), Sanofi, 12, Clinical Trial 2020 GCA and PMR, Abbvie, 12, Clinical Trial 2020-2021 GCA; C. KOENING, None; C. Langford, None; C. McAlear, None; L. Moreland, None; C. Pagnoux, Gsk, 2, 5, 6, Roche, 2, 5, 6, Otuska, 2, Pfizer, 5, 6, Chemocentryx, 2, Astrazeneca, 1; P. Seo, Amgen, 1, Janssen, 1; U. Specks, ChemoCentryx, 2, 5, Genentech, 5, Bristo-Myer Squibb, 5, InflxRX, 5, Astra Zeneca, 1, 5, GSK, 5; A. Sreih, None; K. Warrington, Eli Lilly, 5, Kiniksa, 5; P. Monach, Kiniksa, 1, Celgene, 2, Chemocentryx, 1; P. Merkel, AbbVie, 2, 5, AstraZeneca, 2, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 2, EMDSerono, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Magenta, 2, Neutrolis, 2, Novartis, 2, Pfizer, 2, Sanofi, 5, Star Therapeutics, 2, Takeda, 2, Talaris, 2, UpToDate, 9; C. Lood, Exagen Diagnostic, 5, Eli Lilly, 5, Gilead, 5, Pfizer, 5, Horizon Diagnostic, 5.

To cite this abstract in AMA style:

Michailidou D, Kuley R, Mustelin T, Cuthbertson D, Grayson P, Khalidi N, KOENING C, Langford C, McAlear C, Moreland L, Pagnoux C, Seo P, Specks U, Sreih A, Warrington K, Monach P, Merkel P, Lood C. Neutrophil Extracellular Trap Formation in Patients with Vasculitis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/neutrophil-extracellular-trap-formation-in-patients-with-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neutrophil-extracellular-trap-formation-in-patients-with-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology